Partner with the Leaders
Building Medtech

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics. Visit website.

Yosef Safi Harb

Founder and CEO

Happitech has developed a CE-marked, smartphone-based method for effective remote monitoring of patients. The company's core competencies in artificial intelligence (AI) integration and photoplethysmography (PPG) enable effective and accurate measurement of heart rate and atrial fibrillation. Visit website.

Cynthia Chen

Chairwoman and President

Pulnovo Medical is developing radiofrequency (RF) solutions for the treatment of pulmonary hypertension. PADN is a multipolar synchronous pulmonary artery RF ablation catheter that is intended to treat pulmonary hypertension by ablating the sympathetic nerve at the target site. The device is capable of point-to-point ablation of pulmonary sympathetic nerves. Visit website.

Steven Mickelsen

CEO

Field Medical is developing a next-generation pulsed field ablation (PFA) solution for the treatment of cardiac arrhythmia. The company is building a purpose-built system that incorporates PFA, contact force sensing, electromagnetic localization, and artificial intelligence-enabled mapping capabilities to address the limitations of first-generation PFA technologies and deliver more efficacious therapy. Visit website.

Raj Shah

CEO

GuideAI Health automates the early detection of peripheral vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts from IBM Watson Health. The platform addresses the 90% miss rate in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.  Visit website.

Marcin Golebicki

CEO

EP Solutions is improving clinical outcomes in cardiac resynchronization therapy cases through the use of noninvasive cardiac mapping technology. The company's Amycard 01C is an electrophysiology workstation that records body surface electrograms to create optimized 3D heart models that merge ECG data with anatomical data obtained from medical imaging. EP Solutions' technology helps physicians accurately place CRT leads during implantation and optimize devices during follow-up visits. Visit website.

Martin Stenfeldt

CEO

UNEEG Medical A/S develops cognitive technologies for continuous brain activity monitoring (EEG) to support medical and diagnostic applications. The company specializes in ultra long-term subcutaneous EEG monitoring with its CE-marked 24/7 EEG™ SubQ solution, designed to detect electrographic seizures in daily life. UNEEG’s technology provides objective insights into seizure burden for epilepsy management and aims to alert diabetics of severe hypoglycemia. The company employs approximately 100 people and has recently begun an international market launch. Visit website.

Ori Braun

CEO

ART MEDICAL’s smART+ Platform is designed to address the challenges of malnutrition and reduce the risk of ventilator-associated pneumonia, while also offering features that enhance ICU staff productivity.  Clinically proven to reduce ICU stays and ventilation by 3.3 days and achieve up to 100% feeding efficiency—10 times more effective than standard protocols—smART+ features real-time reflux detection, dynamic nutritional compensation, and continuous tube positioning monitoring to enable precise, data-driven care. Visit website.

Matt Thompson, MD, FRCS

CEO

Life Seal Vascular is developing an aneurysm sac management technology designed to reduce the incidence of Type II endoleaks following Endovascular Aneurysm Repair (EVAR). Type II endoleaks are the leading cause of reintervention after EVAR, and the Life Seal device is compatible with all EVAR systems. Currently in the pre-clinical stage, the company anticipates achieving First In Man (FIM) in Q2 of 2025. Visit website.

Ray Liu

CEO & Co-Founder

Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home. Visit website.

Christopher Carlton

Chairman, Chief Executive Officer and Co-Founder

Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment. Visit website.

Offer Nonhoff

CFO

Nitinotes develops the EndoZip™, the first fully automated endoscopic suturing system for Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive weight-loss procedure. Designed for efficiency, EndoZip enables a single-operator ESG procedure with automated, standardized suturing, reducing variability, procedure time, and training requirements. The system facilitates outpatient treatment with low-risk and predictable outcomes, addressing the growing need for effective, non-surgical obesity interventions. Visit website.

Amrish Nair

Founder/Director

Femom is a comprehensive maternity care platform to improve perinatal outcomes through mobile technology and data science. Designed for in-home and hospital use, Femom's priority solution enables healthcare professionals to gain new insights to the health of the mother and fetus while offering more convenience and information. Visit website.

Joe Landolina

CEO and Co-Founder

Cresilon develops hemostatic solutions to stop traumatic bleeding. The company's initial product, Vetigel, is indicated for use in the veterinary market. Cresilon's proprietary, plant-based hemogel can be applied internally and externally to stop bleeding. The company plans to continue development of its technology for use in human trauma and human surgical applications. Visit website.

Jim Fidacaro

Executive Vice President, Sonion & CEO

Sonion Health is developing a biosensing digital health platform for cuffless blood pressure monitoring, addressing hypertension as a major risk factor for cardiovascular mortality. The technology has been developed over several years by Sonion engineers, known for their expertise in balanced armature receivers, premium microphones, and electromechanical devices. This platform aims to enhance hypertension management through continuous, non-invasive monitoring.

Bernard Peperstraete

Cofounder & CEO

Acuamark Diagnostics is optimizing qPCR and dPCR for early cancer detection and cancer recurrence. Its approach is designed to provide highly accurate results to physicians and patients at a fraction of the cost per life saved. With market leading clinical results in stage 1-4 colorectal cancer, Acuamark is currently developing diagnostics for multiple cancers. US launch of its first products is estimated in 2026.  Visit website.

InkSpace Imaging pioneers a transformative printed electronics platform, initially prioritizing advanced MRI receive coils. These lightweight and flexible coils not only elevate diagnostic imaging, revealing the once invisible, but also expedite scans, enhance patient experiences, reduce the need for sedation, and minimize procedures. Compatible with existing MRI systems and healthcare reimbursement structures, the company's FDA-cleared innovation represents a next-generation approach to accessible, high-quality diagnostics. Visit website.

Yosef Safi Harb

Founder and CEO

Happitech has developed a CE-marked, smartphone-based method for effective remote monitoring of patients. The company's core competencies in artificial intelligence (AI) integration and photoplethysmography (PPG) enable effective and accurate measurement of heart rate and atrial fibrillation. Visit website.

Cynthia Chen

Chairwoman and President

Pulnovo Medical is developing radiofrequency (RF) solutions for the treatment of pulmonary hypertension. PADN is a multipolar synchronous pulmonary artery RF ablation catheter that is intended to treat pulmonary hypertension by ablating the sympathetic nerve at the target site. The device is capable of point-to-point ablation of pulmonary sympathetic nerves. Visit website.

Steven Mickelsen

CEO

Field Medical is developing a next-generation pulsed field ablation (PFA) solution for the treatment of cardiac arrhythmia. The company is building a purpose-built system that incorporates PFA, contact force sensing, electromagnetic localization, and artificial intelligence-enabled mapping capabilities to address the limitations of first-generation PFA technologies and deliver more efficacious therapy. Visit website.

Raj Shah

CEO

GuideAI Health automates the early detection of peripheral vascular disease in CT scans through advanced AI models developed by clinicians and AI/ML experts from IBM Watson Health. The platform addresses the 90% miss rate in current practice by rapidly identifying and reporting subtle disease markers, enabling early intervention before life altering complications develop through disease-to-treatment precision.  Visit website.

Marcin Golebicki

CEO

EP Solutions is improving clinical outcomes in cardiac resynchronization therapy cases through the use of noninvasive cardiac mapping technology. The company's Amycard 01C is an electrophysiology workstation that records body surface electrograms to create optimized 3D heart models that merge ECG data with anatomical data obtained from medical imaging. EP Solutions' technology helps physicians accurately place CRT leads during implantation and optimize devices during follow-up visits. Visit website.

Martin Stenfeldt

CEO

UNEEG Medical A/S develops cognitive technologies for continuous brain activity monitoring (EEG) to support medical and diagnostic applications. The company specializes in ultra long-term subcutaneous EEG monitoring with its CE-marked 24/7 EEG™ SubQ solution, designed to detect electrographic seizures in daily life. UNEEG’s technology provides objective insights into seizure burden for epilepsy management and aims to alert diabetics of severe hypoglycemia. The company employs approximately 100 people and has recently begun an international market launch. Visit website.

Ori Braun

CEO

ART MEDICAL’s smART+ Platform is designed to address the challenges of malnutrition and reduce the risk of ventilator-associated pneumonia, while also offering features that enhance ICU staff productivity.  Clinically proven to reduce ICU stays and ventilation by 3.3 days and achieve up to 100% feeding efficiency—10 times more effective than standard protocols—smART+ features real-time reflux detection, dynamic nutritional compensation, and continuous tube positioning monitoring to enable precise, data-driven care. Visit website.

Matt Thompson, MD, FRCS

CEO

Life Seal Vascular is developing an aneurysm sac management technology designed to reduce the incidence of Type II endoleaks following Endovascular Aneurysm Repair (EVAR). Type II endoleaks are the leading cause of reintervention after EVAR, and the Life Seal device is compatible with all EVAR systems. Currently in the pre-clinical stage, the company anticipates achieving First In Man (FIM) in Q2 of 2025. Visit website.

Ray Liu

CEO & Co-Founder

Vena Vitals is an early stage med-tech company focused on non-invasive continuous blood pressure monitoring. The company's proprietary technology is a soft flexible sensor that conforms to the skin for direct pressure measurement at theradial artery. The company's technology is intended to replace unnecessarily invasive arterial line measurements as well as non-continuous cuff-based methods in both the hospital and at home. Visit website.

Christopher Carlton

Chairman, Chief Executive Officer and Co-Founder

Accure Medical is revolutionizing dermatology with the Accure Laser System, the first 1726nm platform to achieve both CE Mark certification and FDA clearance for the long-term treatment of mild to severe inflammatory acne vulgaris. Leveraging its patented treat-to-temperature technology, the system ensures consistent, safe, and effective results for all skin types. With rapid adoption across the US, Europe, Asia, and the Middle East, Accure is addressing a significant global need with its groundbreaking solution for acne treatment. Visit website.

Offer Nonhoff

CFO

Nitinotes develops the EndoZip™, the first fully automated endoscopic suturing system for Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive weight-loss procedure. Designed for efficiency, EndoZip enables a single-operator ESG procedure with automated, standardized suturing, reducing variability, procedure time, and training requirements. The system facilitates outpatient treatment with low-risk and predictable outcomes, addressing the growing need for effective, non-surgical obesity interventions. Visit website.

Amrish Nair

Founder/Director

Femom is a comprehensive maternity care platform to improve perinatal outcomes through mobile technology and data science. Designed for in-home and hospital use, Femom's priority solution enables healthcare professionals to gain new insights to the health of the mother and fetus while offering more convenience and information. Visit website.

Joe Landolina

CEO and Co-Founder

Cresilon develops hemostatic solutions to stop traumatic bleeding. The company's initial product, Vetigel, is indicated for use in the veterinary market. Cresilon's proprietary, plant-based hemogel can be applied internally and externally to stop bleeding. The company plans to continue development of its technology for use in human trauma and human surgical applications. Visit website.

Jim Fidacaro

Executive Vice President, Sonion & CEO

Sonion Health is developing a biosensing digital health platform for cuffless blood pressure monitoring, addressing hypertension as a major risk factor for cardiovascular mortality. The technology has been developed over several years by Sonion engineers, known for their expertise in balanced armature receivers, premium microphones, and electromechanical devices. This platform aims to enhance hypertension management through continuous, non-invasive monitoring.

Bernard Peperstraete

Cofounder & CEO

Acuamark Diagnostics is optimizing qPCR and dPCR for early cancer detection and cancer recurrence. Its approach is designed to provide highly accurate results to physicians and patients at a fraction of the cost per life saved. With market leading clinical results in stage 1-4 colorectal cancer, Acuamark is currently developing diagnostics for multiple cancers. US launch of its first products is estimated in 2026.  Visit website.

Berk Tas

CEO

Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient. Visit website.

Dimitrios Angelis

Co-Founder

The first osseointegrative biomimetic knee cartilage implant. Visit website.

Dr Shieak Tzeng

Co-founder & CEO

Wellumio is a venture-backed company specializing in portable MRI solutions for acute neuroimaging applications. The company’s core enabling technology is a novel pulse-gradient free nuclear magnetic resonance sensor platform with an initial focus on acute stroke triage and diagnosis. Visit website.

John Brumfield

CEO

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life. Visit website.

Olivier Delporte

CEO

SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory.  Visit website.

Nader Sadrzadeh

CEO

DeepSight Technology develops advanced medical imaging solutions using proprietary sensing technology to enhance diagnostic ultrasound capabilities. The company’s NeedleVue Technology is designed to improve ultrasound-assisted needle guidance, addressing challenges such as complex calibration, reduced sensitivity, and angle dependence. By integrating innovative sensor technology with interventional devices, NeedleVue enables real-time verification of device placement, aiming to reduce procedural uncertainty and streamline interventional workflows. DeepSight Technology operates from the San Francisco Bay Area and Clayton, Missouri, with a focus on expanding the range and effectiveness of diagnostic ultrasound. Visit website.

Nora Herzog

CMO

ConnCons integrates connectivity into infusion consumables to create a cloud to vessel end-to-end digital solution. The system enables safer, faster and automated therapies with a superior patient experience. First clinical applications are targeted at both center-based and home oncological therapy. Visit website.

Ruben Molina

CEO & Co-Founder

INNITIUS develops a medical device that combines intravaginal hardware to measure cervical tissue consistency with shear elastic waves and machine learning algorithms. The device aims to provide diagnostics for multiple women’s health conditions related to childbirth timing, with dedicated algorithms for each specific indication Visit website.

Claus Jessen

Managing Director

Multi-organ failure (MOF) is the main cause of death on ICUs. The ADVOS therapy offers the first and only integrated solution for MOF and acidosis. It includes the support of the liver, lungs, and kidneys in a single device. Patient survival is significantly improved through simultaneous organ detoxification and acid-base balance management. The brand-new blood purification technology revolutionizes detoxification and enables blood pH correction for the first time. The complexities of managing multiple organ failures in a single organism is addressed with a single device. Visit website.

Caitlin Morse

CEO

BrainSpace is developing a solution to simplify critical care in neurocritical patients. BrainSpace is committed to improving the way brain pressure is managed in patients recovering from stroke, traumatic brain injury, and neurosurgery. Currently patients requiring intracranial pressure management must be meticulously monitored and measured hourly by a nurse. The company has developed an automated monitoring solution as an alternative to the antiquated drainage monitoring relying on a manometer-based drain and blood pressure monitor that eliminates the hassle for patients and providers while improving the quality of data being captured for researchers and physicians. Visit website.

Lara Zibners

Co-Founder & Chairman

Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions. Visit website.

Anmol Kapoor

CEO

BioAro is a biotechnology company specializing in genomics, artificial intelligence and blockchain technologies. The company offers whole genome sequencing, microbiome testing, and software solutions to support clinical testing offerings and improve overall efficiency of healthcare practices. Visit website.

James Lancaster

CEO

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants. Visit website.

John von Benecke

CEO

Locate Bio is working to solve some of the most complex degenerative and infectious diseases that affect the muscular skeletal system. Locate utilises Programmed Drug Release to re-align the bioavailability of existing drugs with the underlying biological need. This bio-optimisation step has demonstrated break through improvements in performance in preclinical testing. Locate Bio’s lead product, LDGraft, is entering human clinical studies next year, for the treatment of chronic lower back pain caused by degenerative disc disease. CognitOss Gel is in developed to overcome bacterial biofilm infections around non-viable tissue and orthopaedic implants. Visit website.

Yossi Bar

CEO

LEM Surgical is focused on creating and providing the next generation of robotic surgical systems. The company's flagship product, the Dynamis System, is a multi-arm robotic surgical system that incorporates novel navigation capabilities and has an open architecture for handling concentric tools. Dynamis is intended to be a platform technology for orthopedic and neurosurgical applications. Visit website.

Anastasia Rigas

CEO

Heteron's solution is a hand-held breath analyzer will screen and monitor for biomarkers of gastrointestinal and liver diseases. The technology is intended to replace existing diagnostic testing tools for point-of-care testing, ultimately allowing users to screen themselves and to monitor dietary and long-term medical interventions. Visit website.

David Thompson

CEO

Osteal Therapeutics is a musculoskeletal therapeutics company developing solutions for the treatment of orthopedic infections. The company's lead product, VT-X7, is a drug-device combination that utilizes high concentrations of vancomycin and tobramycin, in conjunction with a drug delivery system, to irrigate infected joint spaces as a result of periprosthetic joint infection in joint replacement patients.  Visit website.

Christopher Haig

Co-Founder/Chief Executive Officer

Efemoral Medical is a clinical stage startup developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant. Visit website.

Karl Stoklosa

CEO

EASEE is Precisis' neurostimulation device that can act in two modes - excitatory and inhibitory. The duality of the device allows its to be used for the treatment of many cerebral diseases, including epilepsy, depression, and cognitive disfunctions caused by stroke. Precisis is currently developing a close-loop system for their EASEE technology, which will allow the device to record brain activity and respond with targeted stimulation. Visit website.

Shahram Sharif

CEO

Liva Healthcare are digitizing personal healthcare. The company's digital health platform provides users with personalized coaching and tailored lifestyle plans. Currently the company offers digital programs for weight management and diabetes prevention. Visit website.

Mohamed Abou-Alam

CEO

Precision Cardiovascular is focused on enhancing the outcomes and quality of life for patients with heart failure. The company is developing a miniature sensor that is placed in the pulmonary artery to continuously collect and analyze data to improve the remote management of cardiovascular diseases. Visit website.

Kambiz Behzadi

President

Novel medical devices to enhance the reliability and safety of orthopedics procedures.  Visit website.

Upma Sharma

President & CEO

Arsenal Medical develops innovative biomaterials to solve challenging and underserved medical problems. Our lead products target neurovascular and trauma conditions providing control of blood flow to tumors and bleeding conditions, such as hemorrhage.  Visit website.

David Marsalek

President

H2 Global is a pioneer in using molecular hydrogen in the fields of healthcare (including biotech and medtech), wellness, beauty, agriculture, and veterinary medicine.  Visit website.

Berk Tas

CEO

Transforming the experience for both patient and clinician in interventional procedures with a 3D augmented reality platform featuring real-time holographic visualization of the patient’s actual anatomy, “floating” over the patient. Visit website.

Dimitrios Angelis

Co-Founder

The first osseointegrative biomimetic knee cartilage implant. Visit website.

Dr Shieak Tzeng

Co-founder & CEO

Wellumio is a venture-backed company specializing in portable MRI solutions for acute neuroimaging applications. The company’s core enabling technology is a novel pulse-gradient free nuclear magnetic resonance sensor platform with an initial focus on acute stroke triage and diagnosis. Visit website.

John Brumfield

CEO

Berlin Heals is developing the C-MIC system, an implantable electroceutical device that delivers a constant, but minimal, electrical direct current that mimics the physiological electrical currents produced by the heart. The device is a near-curative treatment for patients with heart failure that propagates the reverse remodeling of cardiac muscle tissue to restore heart function and size, thereby reducing the symptoms of heart failure and improving quality of life. Visit website.

Olivier Delporte

CEO

SamanTree Medical's Histolog Scanner is a digital microscopy scanner for high-resolution imaging of the surface of fresh tissue. The device utilizes novel, ultra-fast confocal microscopy technology to enable rapid histological assessment in the operating room or pathology laboratory.  Visit website.

Nader Sadrzadeh

CEO

DeepSight Technology develops advanced medical imaging solutions using proprietary sensing technology to enhance diagnostic ultrasound capabilities. The company’s NeedleVue Technology is designed to improve ultrasound-assisted needle guidance, addressing challenges such as complex calibration, reduced sensitivity, and angle dependence. By integrating innovative sensor technology with interventional devices, NeedleVue enables real-time verification of device placement, aiming to reduce procedural uncertainty and streamline interventional workflows. DeepSight Technology operates from the San Francisco Bay Area and Clayton, Missouri, with a focus on expanding the range and effectiveness of diagnostic ultrasound. Visit website.

Nora Herzog

CMO

ConnCons integrates connectivity into infusion consumables to create a cloud to vessel end-to-end digital solution. The system enables safer, faster and automated therapies with a superior patient experience. First clinical applications are targeted at both center-based and home oncological therapy. Visit website.

Ruben Molina

CEO & Co-Founder

INNITIUS develops a medical device that combines intravaginal hardware to measure cervical tissue consistency with shear elastic waves and machine learning algorithms. The device aims to provide diagnostics for multiple women’s health conditions related to childbirth timing, with dedicated algorithms for each specific indication Visit website.

Claus Jessen

Managing Director

Multi-organ failure (MOF) is the main cause of death on ICUs. The ADVOS therapy offers the first and only integrated solution for MOF and acidosis. It includes the support of the liver, lungs, and kidneys in a single device. Patient survival is significantly improved through simultaneous organ detoxification and acid-base balance management. The brand-new blood purification technology revolutionizes detoxification and enables blood pH correction for the first time. The complexities of managing multiple organ failures in a single organism is addressed with a single device. Visit website.

Caitlin Morse

CEO

BrainSpace is developing a solution to simplify critical care in neurocritical patients. BrainSpace is committed to improving the way brain pressure is managed in patients recovering from stroke, traumatic brain injury, and neurosurgery. Currently patients requiring intracranial pressure management must be meticulously monitored and measured hourly by a nurse. The company has developed an automated monitoring solution as an alternative to the antiquated drainage monitoring relying on a manometer-based drain and blood pressure monitor that eliminates the hassle for patients and providers while improving the quality of data being captured for researchers and physicians. Visit website.

Lara Zibners

Co-Founder & Chairman

Calla Lily Clinical Care is a women's health focused company which has developed the proprietary Callavid® platform for intravaginal drug delivery. Initial target indications are in IVF and miscarriage prevention, followed by delivery of live biotherapeutics (LBPs) to reduce antibiotic usage which contributes to antimicrobial resistance (AMR). Further use-cases include effective sample collection to facilitate the next generation of biomarker-based diagnostic tests for endometriosis and a wide range of other conditions. Visit website.

Anmol Kapoor

CEO

BioAro is a biotechnology company specializing in genomics, artificial intelligence and blockchain technologies. The company offers whole genome sequencing, microbiome testing, and software solutions to support clinical testing offerings and improve overall efficiency of healthcare practices. Visit website.

James Lancaster

CEO

Solenic Medical is developing a non-invasive medical device that utilizes alternating magnetic fields to eradicate biofilms that form on implants. The company's platform uses external magnetic coils to destroy infective biofilms on the surface of knee and hip replacement implants, as well as plates and rods for trauma related procedures. Solenic's solution is being developed to replace the expensive and risky two-step revision surgery, which is the current standard of care for chronic infections on medical implants. Visit website.

John von Benecke

CEO

Locate Bio is working to solve some of the most complex degenerative and infectious diseases that affect the muscular skeletal system. Locate utilises Programmed Drug Release to re-align the bioavailability of existing drugs with the underlying biological need. This bio-optimisation step has demonstrated break through improvements in performance in preclinical testing. Locate Bio’s lead product, LDGraft, is entering human clinical studies next year, for the treatment of chronic lower back pain caused by degenerative disc disease. CognitOss Gel is in developed to overcome bacterial biofilm infections around non-viable tissue and orthopaedic implants. Visit website.

Yossi Bar

CEO

LEM Surgical is focused on creating and providing the next generation of robotic surgical systems. The company's flagship product, the Dynamis System, is a multi-arm robotic surgical system that incorporates novel navigation capabilities and has an open architecture for handling concentric tools. Dynamis is intended to be a platform technology for orthopedic and neurosurgical applications. Visit website.

Anastasia Rigas

CEO

Heteron's solution is a hand-held breath analyzer will screen and monitor for biomarkers of gastrointestinal and liver diseases. The technology is intended to replace existing diagnostic testing tools for point-of-care testing, ultimately allowing users to screen themselves and to monitor dietary and long-term medical interventions. Visit website.

David Thompson

CEO

Osteal Therapeutics is a musculoskeletal therapeutics company developing solutions for the treatment of orthopedic infections. The company's lead product, VT-X7, is a drug-device combination that utilizes high concentrations of vancomycin and tobramycin, in conjunction with a drug delivery system, to irrigate infected joint spaces as a result of periprosthetic joint infection in joint replacement patients.  Visit website.

Christopher Haig

Co-Founder/Chief Executive Officer

Efemoral Medical is a clinical stage startup developing a next-generation drug-eluting bioresorbable scaffold for the treatment of PAD. Using a minimally invasive procedure, the Efemoral Vascular Scaffold System is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant. Visit website.

Karl Stoklosa

CEO

EASEE is Precisis' neurostimulation device that can act in two modes - excitatory and inhibitory. The duality of the device allows its to be used for the treatment of many cerebral diseases, including epilepsy, depression, and cognitive disfunctions caused by stroke. Precisis is currently developing a close-loop system for their EASEE technology, which will allow the device to record brain activity and respond with targeted stimulation. Visit website.

Shahram Sharif

CEO

Liva Healthcare are digitizing personal healthcare. The company's digital health platform provides users with personalized coaching and tailored lifestyle plans. Currently the company offers digital programs for weight management and diabetes prevention. Visit website.

Mohamed Abou-Alam

CEO

Precision Cardiovascular is focused on enhancing the outcomes and quality of life for patients with heart failure. The company is developing a miniature sensor that is placed in the pulmonary artery to continuously collect and analyze data to improve the remote management of cardiovascular diseases. Visit website.

Kambiz Behzadi

President

Novel medical devices to enhance the reliability and safety of orthopedics procedures.  Visit website.

Upma Sharma

President & CEO

Arsenal Medical develops innovative biomaterials to solve challenging and underserved medical problems. Our lead products target neurovascular and trauma conditions providing control of blood flow to tumors and bleeding conditions, such as hemorrhage.  Visit website.

David Marsalek

President

H2 Global is a pioneer in using molecular hydrogen in the fields of healthcare (including biotech and medtech), wellness, beauty, agriculture, and veterinary medicine.  Visit website.